194 related articles for article (PubMed ID: 37694771)
1. Factor XI as a therapeutic target in neuroinflammatory disease.
Taskin B; Kohs TCL; Shatzel JJ; Puy C; McCarty OJT
Curr Opin Hematol; 2024 Jan; 31(1):32-38. PubMed ID: 37694771
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological targeting of coagulation factor XI attenuates experimental autoimmune encephalomyelitis in mice.
Kohs TCL; Fallon ME; Oseas EC; Healy LD; Tucker EI; Gailani D; McCarty OJT; Vandenbark AA; Offner H; Verbout NG
Metab Brain Dis; 2023 Oct; 38(7):2383-2391. PubMed ID: 37341855
[TBL] [Abstract][Full Text] [Related]
3. Factor XI contributes to thrombin generation in the absence of factor XII.
Kravtsov DV; Matafonov A; Tucker EI; Sun MF; Walsh PN; Gruber A; Gailani D
Blood; 2009 Jul; 114(2):452-8. PubMed ID: 19351955
[TBL] [Abstract][Full Text] [Related]
4. Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation.
Stroo I; Zeerleder S; Ding C; Luken BM; Roelofs JJTH; de Boer OJ; Meijers JCM; Castellino FJ; van 't Veer C; van der Poll T
Thromb Haemost; 2017 Jul; 117(8):1601-1614. PubMed ID: 28492700
[TBL] [Abstract][Full Text] [Related]
5. Differential Roles for the Coagulation Factors XI and XII in Regulating the Physical Biology of Fibrin.
Sylman JL; Daalkhaijav U; Zhang Y; Gray EM; Farhang PA; Chu TT; Zilberman-Rudenko J; Puy C; Tucker EI; Smith SA; Morrissey JH; Walker TW; Nan XL; Gruber A; McCarty OJT
Ann Biomed Eng; 2017 May; 45(5):1328-1340. PubMed ID: 27933406
[TBL] [Abstract][Full Text] [Related]
6. Regulation of blood coagulation factors XI and XII in patients with acute and chronic cerebrovascular disease: a case-control study.
Kraft P; Drechsler C; Gunreben I; Heuschmann PU; Kleinschnitz C
Cerebrovasc Dis; 2014; 38(5):337-43. PubMed ID: 25427539
[TBL] [Abstract][Full Text] [Related]
7. Factor XII inhibition reduces thrombus formation in a primate thrombosis model.
Matafonov A; Leung PY; Gailani AE; Grach SL; Puy C; Cheng Q; Sun MF; McCarty OJ; Tucker EI; Kataoka H; Renné T; Morrissey JH; Gruber A; Gailani D
Blood; 2014 Mar; 123(11):1739-46. PubMed ID: 24408325
[TBL] [Abstract][Full Text] [Related]
8. Model-dependent contributions of FXII and FXI to venous thrombosis in mice.
Grover SP; Olson TM; Cooley BC; Mackman N
J Thromb Haemost; 2020 Nov; 18(11):2899-2909. PubMed ID: 33094904
[TBL] [Abstract][Full Text] [Related]
9. Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation.
Tweddell JS; Kharnaf M; Zafar F; Riggs KW; Reagor JA; Monia BP; Revenko A; Leino DG; Owens AP; Martin JK; Gourley B; Rosenfeldt L; Palumbo JS
Blood Adv; 2023 Apr; 7(8):1404-1417. PubMed ID: 36240297
[TBL] [Abstract][Full Text] [Related]
10. Cytoprotective E-WE thrombin reduces disease severity in a murine model of relapsing-remitting multiple sclerosis.
Verbout NG; Su W; Pham P; Jordan KR; Kohs TCL; Tucker EI; McCarty OJT; Sherman LS
Am J Physiol Cell Physiol; 2024 Jan; 326(1):C40-C49. PubMed ID: 37955120
[TBL] [Abstract][Full Text] [Related]
11. Coagulation factors XI and XII as possible targets for anticoagulant therapy.
Kluge KE; Seljeflot I; Arnesen H; Jensen T; Halvorsen S; Helseth R
Thromb Res; 2022 Jun; 214():53-62. PubMed ID: 35490644
[TBL] [Abstract][Full Text] [Related]
12. Increased factor XI but not factor XII is associated with enhanced inflammation and impaired fibrin clot properties in patients with eosinophilic granulomatosis with polyangiitis.
Natorska J; Ząbczyk M; Mastalerz L; Undas A
Clin Exp Rheumatol; 2024 Apr; 42(4):822-827. PubMed ID: 38079326
[TBL] [Abstract][Full Text] [Related]
13. Factor XII activation is essential to sustain the procoagulant effects of particulate matter.
Kilinç E; Van Oerle R; Borissoff JI; Oschatz C; Gerlofs-Nijland ME; Janssen NA; Cassee FR; Sandström T; Renné T; Ten Cate H; Spronk HM
J Thromb Haemost; 2011 Jul; 9(7):1359-67. PubMed ID: 21481175
[TBL] [Abstract][Full Text] [Related]
14. Factor XII-independent activation of factor XI in plasma: effects of sulfatides on tissue factor-induced coagulation.
Gailani D; Broze GJ
Blood; 1993 Aug; 82(3):813-9. PubMed ID: 8338946
[TBL] [Abstract][Full Text] [Related]
15. The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials.
DeLoughery EP; Olson SR; Puy C; McCarty OJT; Shatzel JJ
Semin Thromb Hemost; 2019 Jul; 45(5):502-508. PubMed ID: 31216587
[TBL] [Abstract][Full Text] [Related]
16. New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors.
Chan NC; Weitz JI
Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):1755-1763. PubMed ID: 37650326
[TBL] [Abstract][Full Text] [Related]
17. Genetic analysis of a pedigree with combined factor XII and factor XI deficiency.
Ye X; Feng Y; Ding Q; Dai J; Wang X
Blood Coagul Fibrinolysis; 2011 Mar; 22(2):118-22. PubMed ID: 21192253
[TBL] [Abstract][Full Text] [Related]
18. Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX.
Visser M; van Oerle R; Ten Cate H; Laux V; Mackman N; Heitmeier S; Spronk HMH
Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):103-111. PubMed ID: 31766871
[TBL] [Abstract][Full Text] [Related]
19. Targeting the RNA-Binding Protein HuR Alleviates Neuroinflammation in Experimental Autoimmune Encephalomyelitis: Potential Therapy for Multiple Sclerosis.
Borgonetti V; Sanna MD; Lucarini L; Galeotti N
Neurotherapeutics; 2021 Jan; 18(1):412-429. PubMed ID: 33200288
[TBL] [Abstract][Full Text] [Related]
20. Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives.
Vlădăreanu AM; Roşca A
Rom J Intern Med; 2024 Jun; 62(2):91-100. PubMed ID: 38153875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
